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The pandemic caused by the novel coronavirus SARS-CoV-2 
manifests clinically in different ways. Most patients infected with 
SARS-CoV-2 exhibit mild to moderate symptoms and approximately 
40 - 50% are asymptomatic. However, some patients develop severe 
disease that manifests as the acute respiratory distress syndrome 
(ARDS), multi-organ failure and/or septic shock. The virus is 
transmitted via aerosol, fomite and possibly faecal-oral routes.[1]
Most individuals who are admitted to hospital present with 
pneumonia and hypoxaemia.[1] Some individuals develop coagulation-
related pathologies and multiple-organ failure, which sets COVID-19 
apart from hyperinflammatory states seen in other diseases.[2] 
Methods 
PubMed and other databases were accessed using the search words 
‘COVID-19 AND pathophysiology’, and ‘COVID-19 AND treatment 
AND therapeutic strategies’.  The authors then evaluated published 
studies on the pathophysiology, severity and therapeutic options 
based on data from these sources. This is not an exhaustive systematic 
review, or a meta-analysis, but rather a descriptive review, in an ever-
changing field, of some of the key pathogenetic mechanisms to have 
emerged in a disease whose existence we have known about for less 
than a year.
Pathogenesis of COVID-19
SARS-CoV-2 infects the host by binding to angiotensin-converting 
enzyme 2 (ACE-2). There is now evidence that the virus infects 
multiple pulmonary cell types, including bronchial epithelium, with 
the virus being detected in abundance in ciliated cells, non-ciliated 
mucus-secreting (goblet) cells, club cells and alveolar cells.[3-5] The 
receptor is also found in the kidney, heart and on gut cells.[6] SARS-
CoV-2 also targets the immune system, where nucleocapsid proteins 
target B cells and small blood vessels which is thought to contribute 
to systemic vasculitis and immune dysfunction.[4] Other receptors 
on human cells likely to promote entry of SARS-CoV-2 include 
transmembrane serine protease 2,[7] sialic acid[8] and extracellular 
matrix metalloproteinase inducer CD147,[9] which are present in 
vascular endothelial cells, arterial smooth-muscle cells and other 
cell types. Descriptive studies on the presence of ACE-2 and other 
(co)receptor proteins and/or transcripts[10] imply that they may be 
necessary but not that they are sufficient for viral binding. As a result 
of viral binding to ACE-2, concern has been expressed about using 
renin-angiotensin-aldosterone system inhibitors, such as angiotensin 
II receptor blockers (ARBs) and ACE inhibitors for the treatment of 
hypertension in COVID-19 patients.[11-13] However, two large studies 
have demonstrated that there is no evidence for an increased risk of 
COVID-19 as a result of ACE inhibitor or ARB treatment.[14,15] The 
American Heart Association has stated that ‘Patients taking ACE-i 
and ARBs who contract COVID-19 should continue treatment, 
unless otherwise advised by their physician.’[16] 
The hyperinflammatory state that characterises COVID-19 
appears to be linked in part to endothelial dysfunction which may 
result from viral binding to endothelial and pulmonary vascular 
smooth-muscle cell ACE-2 receptors.[3-5,10] Recent evidence has 
shown that interleukin (IL)-6, which plays an important role in 
the development and progression of the inflammatory process 
during viral infection, can be induced by angiotensin II through a 
mineralocorticoid receptor-dependent mechanism, contributing to 
the hyperinflammatory state.[17]
Immune dysregulation 
Following infection, the host attempts to eliminate the virus by 
inducing an antiviral immune response, which includes both innate 
and adaptive immune systems.[18] The innate immune response is 
invoked at the first encounter with the virus and provides an initial 
mechanism for eliminating the pathogen. However, if the response is 
defective, the virus will proliferate and cause widespread damage to 
affected tissues.[19] Infected tissues undergo pyroptosis, which results 
in the release of damaged associated molecular patterns (DAMPs). 
These molecular patterns are recognised as ‘foreign’ by epithelial 
cells, endothelial cells and alveolar macrophages, which results in 
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an uncontrolled innate inflammatory response in the lungs. This is 
mediated by pro-inflammatory cytokines.[18-20]
One of the consequences of SARS-CoV2 infection is the activation 
of neutrophils that release neutrophil extracellular traps (NETs).[21] 
NETs are comprised of nuclear and mitochondrial DNA and protein 
material from nuclear chromatin and cytosolic granules. One variant 
of NET, termed suicidal NETosis, results in cell death and the 
release of reactive oxygen species. Various molecules can promote 
this type of NET, including DAMPs. Damaged neutrophils have a 
negative redox potential that maintains endogenous self-antigens, 
such as high-mobility group box 1 (HMGB1) in a fully reduced 
form (fr-HMGB1). HMGB1 promotes activation of the receptor for 
advanced glycation end products (RAGE), which further triggers 
neutrophil-mediated inflammation.[21] Activation of toll-like receptor 
4 (TLR-4) in turn acts as a procoagulant factor through platelet 
stimulation of this receptor.
The induction of a proinflammatory process is reflected in raised 
plasma concentrations of a number of cytokines and chemokines 
which include IL-1 beta (IL-1β), IL-1RA, IL-6, IL-7, IL-8, IL-9, 
IL-10, fibroblast growth factor (FGF), granulocyte colony stimulating 
factor (G-CSF), granulocyte macrophage colony stimulating factor 
(GM-CSF), interferon-gamma (IFN-γ), IFN-γ inducible protein (IP)-
10, monocyte chemotactic protein (MCP)-1, monocyte inhibitory 
protein (MIP)-1A, MIP-1B, platelet-derived growth factor (PDGF), 
tumour necrosis factor-alpha (TNF-α), and vascular endothelial 
growth factor (VEGF).[3,18,22-24] These cytokines and chemokines 
drive inflammation. In mild diseases with limited inflammation, 
this pro-inflammatory state results in the production of neutralising 
antibodies by plasma cells driven by virus-specific T cells, and 
eventually progresses to eradication of the virus and recovery. 
However, in severe COVID-19 there is an exaggerated degree of 
inflammation which is deleterious to the host. 
In COVID-19, the accumulation of pro-inflammatory cytokines 
may result in the cytokine release syndrome (CRS or ‘cytokine 
storm’) with systemic inflammation and damage to the respiratory 
infrastructure, as well as a hypercoagulable state as a consequence of 
endothelial injury. In patients with more severe disease, higher levels 
of IL-2, IL-6, IL-7 IL-10, G-CSF, IP-10, MCP-1, MIP-1A and TNF-α 
have been observed compared with patients with milder infection 
and those who do not require admission to an intensive care unit 
(ICU).[25] 
Recent evidence indicates that the surge of cytokines thought 
to be the driver of the CRS in COVID-19 may not be as high as 
is seen in other causes of ARDS, and the CRS itself lacks a clear 
definition with some authors denying its existence. In essence, the 
presence of immune mediators such as chemokines, interferons, 
TNF-α, interleukins and others is part of a fundamental immune 
response needed for innate infection control. It has been proposed 
that in the CRS, these immune mediators are raised to levels that are 
detrimental to the host. Of particular interest is IL-6, a key mediator 
of acute inflammation, which has gained much attention over the 
course of the pandemic. IL-6 has become a therapeutic target for 
COVID-19. In randomised clinical trials conducted by the National 
Heart, Lung and Blood Institution’s ARDS Network, it was reported 
that patients with severe disease who develop ARDS due to COVID-
19 have IL-6 levels 10 - 40-times higher than the upper limit of 
normal.[26] The phenotype associated with typical ARDS manifests as 
elevated plasma levels of pro-inflammatory cytokines, an increased 
propensity to shock and poor clinical outcomes. While the phenotype 
in COVID-19-related ARDS is consistent with what is expected in a 
cytokine storm, IL-6 levels in ARDS due to other causes are 10 - 200 
times higher than those seen in ARDS due to COVID-19, casting 
doubt on the presence of a CRS in COVID-19.[26] There is a need to 
identify patients in whom targeted immunotherapeutic monoclonal 
antibodies are effective, and to determine biomarkers that could 
potentially predict the response, to further understand the CRS in 
COVID-19.[26]
Evidence for macrophage involvement in the pathogenesis of SARS-
CoV-2 is undisputed, and it has been suggested that macrophages in 
the lungs and other organs in COVID-19 are newly derived from 
circulating monocytes rather than specialised local pre-existing 
resident tissue macrophages. Circulating monocytes exit the bone 
marrow via the CC chemokine receptor 2 (CCR2). Trials targeting 
the chemokine receptors (involved in regulation of monocytes and in 
T-cell migration) are ongoing.[2] 
Coronaviruses are different from other respiratory viruses in 
that they induce interferons. INF-α and INF-β can drive antiviral 
immunity, but dysregulated release leads to extensive pathology 
as seen in patients with severe COVID-19. Normally, interferons 
mainly have antiviral activity, activating natural killer (NK) cells 
and macrophages and upregulating the expression of major 
histocompatibility complex (MHC) antigens which facilitate binding 
of the virus to T cells. Whereas INF-α and INF-β are expressed almost 
everywhere, INF-λ affects mostly epithelial cells and has an effect 
on T-helper type 2 (TH2) cells; it is also immunosuppressive. As a 
therapeutic intervention, blocking this cytokine might potentially 
prevent the CRS.[27] The unchecked production of INF-γ also leads 
to dysregulated macrophage activation. Clinical trials assessing the 
effects of INF-γ blockade in patients with respiratory distress and 
severe disease are under way.[27] 
Host factors promoting COVID-19 severity 
Age 
Advanced age (>60 years) and certain comorbidities are presumed to 
contribute to a dysregulated immune response, which is less efficient 
at pathogen elimination.[28] This process describes immunosenescence 
and has been attributed to altered dendritic cell maturation and 
defective T-cell activation. With increased age, the combination of 
thymic degeneration and the continuous conversion of naïve T cells 
into memory T cells as a result of antigen challenge results in the 
T-cell receptor repertoire being reduced and replaced by oligoclonal 
memory T cells.[29] Age-related alterations in the T-cell repertoire 
have significant clinical implications, since naïve T cells have mostly 
been replaced. This is of particular concern in the production of a 
vaccine for COVID-19 if one draws a parallel with the poor outcomes 
seen with the yearly influenza vaccine among the elderly.[29] Ageing is 
considered to be a pro-inflammatory state. Taken together, changes 
seen with advanced age including a dysregulated immune response and 
an augmented inflammatory state can exacerbate disease severity.[18] A 
recent study has shed light on the effects of age on pulmonary defence 
mechanisms: specific factors in the antioxidant defence system of 
alveolar type II cells, including superoxide dismutase 3 and activating 
transcription factor 4 (an endoplasmic reticulum stress sensor), 
become less effective with age.[30] 
In contrast to those of advanced age, children are less severely 
affected despite having higher viral titres; 50% of individuals less 
than 18 years of age experience mild disease or are asymptomatic, 
and less than 6% develop severe symptomatic infection. Mortality in 
this group is extremely low in comparison with adults and especially 
the elderly.[31] 
Comorbidities 
Comorbidities appear to be the most consistent feature in individuals 
with severe disease, with more than 30% of symptomatic individuals 
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having a comorbid condition. The vast majority of severe COVID-19 
cases and deaths occur in individuals with an underlying chronic 
condition including obesity, diabetes, chronic respiratory disease, 
diseases of the cardiovascular system (especially hypertension) and 
malignancy.[18] These conditions are all associated with an impaired 
immune response, and when superimposed on a hyperinflammatory 
state, contribute to disease severity. These comorbidities are also 
associated with endothelial dysfunction.[32] 
In addition, there is increasing evidence that a deficiency in 
nicotinamide adenine dinucleotide (NAD+) is associated with disease 
severity in COVID-19. Hypertension, obesity, diabetes and advanced 
age are all associated with oxidative stress and pre-existing depletion 
of NAD+. When patients with comorbidities are infected with 
SARS-CoV-2, this reduces NAD+ dependent silent information 
regulator 1 (SIRT1) production.[33] SIRT1 controls and modifies the 
inflammatory response and, together with other members of the 
sirtuin family, constitutes part of the primary defence against DNA 
and RNA viral pathogens. Nutritional support with NAD+ precursors 
and SIRT1 activators (including zinc and nicotinic acid) has a 
rational scientific basis.[33]
Genetic factors 
HLA haplotypes and SARS-CoV-2 infection[19] 
Human leukocyte antigen (HLA) diversity is a product of selective 
pressure during pathogen co-evolution. Genetic susceptibility to 
various infectious diseases such as tuberculosis, leprosy, HIV, hepatitis 
B and influenza has been well established. This susceptibility is 
conferred in part by HLA loci. For example, HLA-A*11, HLA-B*35, 
and HLA-DRB1*10 confer susceptibility to influenza A(H1N1)pdm09 
infection. Hence it is important to identify possible HLA haplotypes 
which may be associated with an immune response to SARS-CoV-2. 
This information will be beneficial for vaccine development. It may 
also help in developing novel treatment strategies.
ARDS 
Complex genetic and environmental risk factors contribute to the 
development of ARDS. More than 80 genes have been implicated, 
with the most common variants being found in the genes for IL-6, 
IL-10, ACE, IL-1 receptor antagonist (IL1RN), mannose-binding 
lectin 2 (MBL-2), nicotinamide phosphoribosyltransferase (NAMPT) 
and VEGF-A. These gene products play an important role in the 
response to external stimuli and in signal transduction, as well as 
in the immune response, chemotaxis and cell proliferation.[34] Since 
most of this information has been extrapolated from European 
populations, similar studies in African populations (which have 
extensive genomic diversity) would be important. 
Prior to COVID-19 and in other diseases with ARDS, in a genome-
wide association study Christie et al.[35] identified variants associated 
with ARDS in the genes for tyrosine phosphatase receptor type f 
polypeptide interacting protein (liprin) and alpha 1 (PPF1A1), as well as 
genes encoding IL-10, angiopoietin 2 (ANGPT2), Fas cell surface death 
receptor (FAS) and myosin light chain kinase (MYLK). Lee et al.[36] 
identified MYLK to be associated with ARDS and ‘ventilator free days’, 
linking MYLK to ARDS susceptibility. Shortt et al.[37] presented three 
genomic variants that may be involved in enhancing the susceptibility, 
severity and clinical outcome of ARDS that include arylsulfatase D gene 
(ARSD), X Kell blood group complex subunit related family member 3 
gene (XKR3) and zinc finger protein 335 (ZNF335).
COVID-19
A genome-wide analysis study (GWAS) in Italian and Spanish patients 
with confirmed SARS-CoV-2 found that loci on chromosomes 3 and 
9 were linked to SARS-CoV-2-induced respiratory failure.[38] These 
loci include: rs11385942 insertion-deletion GA or G variant at locus 
3p21.31 and rs657152 A or C SNP at locus 9q34.2.[38] The association 
signal at locus 3p21.31 consists of 6 genes that include CCR9, CXCR6, 
FYCO1, LZTFL1, SLC6A20 and XCR1. Rs11385942 contains the risk 
allele GA and has been linked to the reduced expression of CXCR6 
and increased expression of SLC6A20 and LZTFL1, which is highly 
expressed in pulmonary bronchial and alveolar cells in humans.[38] 
When patients on mechanical ventilation were compared with 
those on supplemental oxygenation, the former were more likely 
to have the 3p21.31 (rs11385942) risk allele.[38] This suggests that 
the 3p21.31 locus could be involved in enhanced susceptibility to 
more severe disease. This study also showed that patients with blood 
group A were found to be at a higher risk of developing SARS-
CoV-2 compared with other blood groups, while blood group O 
had a protective effect when compared with other blood groups. 
Two subsequent studies based on clinical data and outcomes, but 
which did not involve a GWAS, yielded similar outcomes. Hoilend 
et al.[39] reported that patients with blood group A or AB had an 
increased risk for requiring mechanical ventilation, continual renal 
replacement therapy and prolonged ICU stay when compared with 
patients with O and B blood groups, while Barnkob et al.[40] reported 
that ABO blood groups could define susceptibility to infection (with 
O blood group being protective) but not hospitalisation or death 
from COVID-19. However, the possible role of blood groups in 
determining COVID-19 susceptibility and severity has been called 
into question.[41]
Other contributors to disease severity and complications 
of SARS-CoV-2 infection 
The presence of ACE-2 receptors on endothelial cells, pericytes and 
smooth-muscle cells in most organs suggests that SARS-CoV-2, once 
present in the circulation, may easily spread to all body systems. 
A recent study of postmortem lung tissues from patients who died 
from COVID-19 and influenza A (H1N1) found a significant number 
of ACE-2-positive endothelial cells and significant morphological 
changes with disruption of intercellular junctions, cell swelling, and 
a loss of contact with the basement membrane.[42] These findings 
suggest that endothelial dysfunction, including systemic vasculitis 
and endothelial cell apoptosis, contributes to the increased risk of 
developing venous thromboembolic disease and inflammation in 
various organs in COVID-19.[43-45] It should be borne in mind, as 
indicated above, that ACE-2 may be necessary but not sufficient 
for SARS-CoV-2 entry; caution should therefore be employed in 
interpreting localisation data. 
It is also probable that, as with other infectious diseases, SARS-
CoV-2 can activate coagulopathy through inflammatory responses. 
Platelet-dense granules contain polyphosphates which are secreted 
upon activation.[46] Polyphosphates released from activated platelets 
accelerate factor V activation, inhibit the anticoagulant activity of 
tissue factor pathway inhibitor, promote factor XI activation by 
thrombin, and contribute to the synthesis of thicker fibrin strands 
that are resistant to fibrinolysis.[47] This suggests a link between the 
immune system and the coagulation cascade in COVID-19, as with 
all sepsis aetiologies.
In addition, a new mechanism has been described in which ACE-2 
receptor-bound SARS-CoV-2 induces luminal expression of tissue 
factor (TF). TF then binds to circulating coagulation factor VII, 
resulting in production of excess thrombin and fibrin and increased 
intrinsic clot formation.[48] A number of cytokines (primarily TNF-α) 
upregulate NAD phosphate (NADPH) oxidase and nuclear factor-
kappa B (NF-κ B) to induce TF production in endothelial cells.[48] 
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Inflammation also results in activated pulmonary vascular endothelial 
cells and endothelial injury, with a resultant prothrombotic state in 
the pulmonary vasculature.[49] Vascular endothelial injury causes 
further thrombocytopenia (through peripheral platelet destruction), 
a reduction in natural anticoagulants and haemostatic activation, and 
manifests as diffuse intravascular coagulation in COVID-19.[49] 
Multisystem inflammatory syndrome in children 
A rare but severe form of COVID-19 has been reported in children 
and is referred to as the multisystem inflammatory syndrome in 
children (MIS-C).[50] Clinical features of MIS-C are reported to be 
similar to but distinct from Kawasaki disease. 
MIS-C is not an adult version of the CRS. Ongoing studies suggest 
that antibodies to SARS-CoV-2 actually permit viral entry into 
affected cells[51] or that immune complexes may be stimulatory to the 
immune system.[51] Cross-reactivity between a microbial antigen and 
host tissues, where epitopes are shared (molecular mimicry), is also 
a possibility.[52] Lastly, it is possible that SARS-CoV-2 may act as an 
adjuvant factor for the, as yet, unknown trigger in MIS-C.[50]
Implications for therapy
Multiple therapeutic strategies are being considered for patients with 
more severe COVID-19 and these are summarised in Table 1.[4,48,53-73] 
Some (in bold in the table) are effective and widely used therapies 
for severe COVID-19. The jury is still out as to the value of antiviral 
therapies. Recent trials using lopinivar/ritonavir as a single agent have 
shown no benefit.[54] A variety of antiviral agents are being studied 
in various clinical trials.[74] A study published in The Lancet reported 
that remdesivir was not associated with a difference in time to clinical 
improvement (hazard ratio 1.23; 95% confidence interval (CI) 0.87 - 
1.75).[55] In a subsequent study, in patients with symptom duration of 
10 days or less, those treated with remdesivir had a numerically faster 
Table 1. Pharmacological modalities for treatment of COVID-19*
Pharmacological modality Mechanism of action Benefit Reference
Angiotensin–aldosterone system 
inhibitors, such as ARBs and ACE 
inhibitors





Lopinivar/ritonavir Broad-spectrum antiviral None Cao et al.[54]
Remdesivir Antiviral Conflicting studies 
Some endpoints not statistically 
significant
Most recent WHO report finds no 
benefit
Wang et al.,[55] Beigel et al.,[56] 
Pan et al.[57]
Favipiravir Antiviral None Siemieniuk et al.[58]
Umifenovir Antiviral None Siemieniuk et al.[58]
Tocilizumab IL-6 receptor blockage Several ongoing RCTs Toniati et al.,[59] Alzghari 
and Acuña,[60]
Menzella et al.[61]
Anakinra IL-1 monoclonal antibody Studies not completed or reported Jamilloux et al.[62]
Adalimumab TNF-α monoclonal antibody Studies not completed or reported Jamilloux et al.[62]
Hydroxychloroquine Nonspecific anti-inflammatory None
Adverse events
Molina et al.,[63] Cortegiani 
et al.[64]





Vitamin D Multiple scientific benefits Unproven
Scientific rationale
Marik et al.[66]
Vitamin C Multiple scientific benefits Unproven Cheng[67]
Mesenchymal stromal/stem cell therapy Counter inflammation and 
apoptosis
Unproven Cao,[4] Gupta et al.[68]
Nutritional components including 
glutathione peroxidase, lipoic 
acid, ferulic acid, sulforaphane, 
N-acetylcysteine, glycine, citrulline and 
high-dose folate
Reducing NADPH oxidase 
dependent tissue factor expression
Unproven Dinicolantonio and 
McCarty[48]
Intravenous immunoglobulin Immune boosting Unproven
Conflicting data
Galeotti et al.[69]
Corticosteroids Anti-inflammatory Increasing evidence
One significantly positive study
Richards and Feldman,[70] 
Wu et al.[71]
Convalescent serum Antibody boosting None Montelongo-Jauregui et al.[72]
Anticoagulation Reduce thrombi formation Positive results in severe disease Tang et al.[73]
ARBs = angiotensin II receptor blockers; ACE = angiotensin-converting enzyme; IL = interleukin; RCT = randomised controlled trial; TNF-α = tumour necrosis factor alpha; 
NAD+ = nicotinamide adenine dinucleotide; SIRT1 = silent information regulator 1; NADPH = NAD phosphate.
*Effective and widely used therapies for severe COVID-19 shown in bold.
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time to clinical improvement compared with those receiving placebo 
(hazard ratio 1.52; 95% CI 0.95 - 2.43).[56] 
Several clinical trials have assessed the efficacy of hydroxy-
chloroquine (alone or in combination) based on its nonspecific anti-
inflammatory effects seen in other conditions. Data generated thus 
far indicate that it lacks efficacy and there may be safety concerns 
related to its use.[63]
Trials are under way to assess the potential benefits of therapies 
that block IL-6, its receptor, IL-1β, and GM-CSF, as well as other 
myeloid-derived inflammatory cytokines, especially TNF-α. IL-1 is 
a crucial element in the development of the CRS in patients with 
severe disease. Anakinra (an IL-1 antagonist) has been shown to be 
of benefit in patients with severe sepsis complicated by macrophage 
activation syndrome (MAS); studies with anakinra in COVID-19 
may be useful to further understand the disease process, as well 
as providing a potential therapeutic option.[25] TNF-α is one of 
the major drivers of inflammatory responses. TNF-α antagonistic 
drugs are used widely in management of rheumatological diseases. 
TNF-α levels are moderately elevated in SARS-CoV-2 patients. 
Targeting TNF-α has thus been identified as a potential therapeutic 
option, and clinical trials have been initiated to assess the effect of 
adalimumab, an anti-TNF monoclonal antibody.[24] Strategies to 
interfere with receptor binding and cytokine signalling may unveil 
crucial pathogenetic mechanisms and possibly therapeutic options to 
prevent severe disease. 
It is possible that high-dose intravenous immunoglobulin (IVIg) 
may have a beneficial effect in the hyperinflammatory phase but the 
mechanism of action is not known.[69,75] It is particularly widely used 
in children with MIS-C.
Several nutritional components may have theoretical, but as 
yet untested, benefits in reducing NADPH oxidase dependent TF 
expression, including glutathione peroxidase, lipoic acid, ferulic acid, 
sulforaphane, N-acetylcysteine, glycine, citrulline and high-dose 
folate.[48] Studies are planned or are under way to identify nutritional 
supplements which may help with NAPDH reduction as part of the 
treatment regimen in COVID-19.[48]
The use of corticosteroids for the treatment of COVID-19, based on 
their ability to suppress an exaggerated inflammatory response, has 
been widely deliberated in medical literature. Currently corticosteroid 
use for treatment of COVID-19 is recommended, mostly based on 
evidence from the RECOVERY trial (Randomized Evaluation of 
COVID Therapy).[76] The RECOVERY trial reported that the use of 
corticosteroids (dexamethasone and methylprednisone) reduced the 
risk of mortality, the need for mechanical ventilation and duration 
of hospital stay.[76] It is important to note that corticosteroids have 
shown no benefit in patients who do not require respiratory support.[70] 
The Surviving Sepsis Guideline (SSG) for COVID-19 recommends 
the use of low-dose corticosteroids in COVID-19 patients with 
shock who are not responding to treatment and in patients requiring 
mechanical ventilation, while it advises against steroid use for patients 
with COVID-19 in respiratory failure but without ARDS.[77] Studies 
from China propose the use of corticosteroids early in COVID-19 
based on the observation of reduced disease escalation and improved 
outcomes.[71]
Randomised clinical trials on the treatment of children with 
MIS-C have not been reported but certain therapies are widely used, 
including systemic steroids, high-dose IVIg and cytokine inhibitors. 
In addition, patients require respiratory and inotropic support.[78]
Conclusions
The disease course of COVID-19, including its molecular and 
mechanistic components, is becoming clearer. Three distinct stages 
of clinical progression based on immunological parameters have 
been described. The first involves an antiviral response with an 
immediate potent interferon release which brings the infection under 
control and potentially eradicates the virus. During the second stage, 
a delayed interferon response may ensue which would nonetheless 
result in extensive damage. If the second stage fails to achieve 
infection resolution, there is progression to a more severe third 
stage in which hyperinflammation with dysregulated macrophage 
activation and widespread coagulation ensues. Patients who progress 
to stage three may also have dysregulated repair mechanisms and 
fibrosis.[2] The systemic hyperinflammation seen in patients infected 
with SARS-CoV-2 is believed by many to be the nidus of the 
pathology in severe disease, although a clearer definition of the CRS, 
particularly in relation to other causes, is needed. It is critical that the 
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